Second-line chemotherapy for melanoma
Author Information
Author(s): Propper D J, Braybrooke J P, Levitt N C, O'Byrne K, Christodoulos K, Han C, Talbot D C, Ganesan T S, Harris A L
Primary Institution: ICRF Medical Oncology Unit, Churchill Hospital, Headington, Oxford, OX3 7LJ, UK
Hypothesis
Is the DBPT chemotherapy regimen effective for patients with malignant melanoma previously treated with dacarbazine?
Conclusion
The DBPT regimen is not effective for melanoma patients who are primarily refractory to DTIC, but may benefit a small subgroup.
Supporting Evidence
- Thirty-five patients received the DBPT regimen.
- Group 1 had 17 patients who were switched directly from DTIC to DBPT.
- Group 2 had 18 patients who were not immediately switched and included those with partial response or stable disease.
Takeaway
Doctors tested a new combination of medicines for melanoma patients who didn't respond to an earlier treatment, and found it didn't work for most, but might help a few.
Methodology
Patients were divided into two groups based on their previous treatment responses and received the DBPT regimen.
Limitations
The study only included a small number of patients and did not find significant effectiveness in the primary refractory group.
Participant Demographics
Patients with progressive metastatic melanoma previously treated with dacarbazine.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website